Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy

Sadako Akashi-Tanaka, Mutsuko Omatsu, Chikako Shimizu, Masashi Ando, Kotoe Terada, Tadahiko Shien, Takayuki Kinoshita, Yasuhiro Fujiwara, Kunihiko Seki, Tadashi Hasegawa, Takashi Fukutomi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Neoadjuvant endocrine therapy (NAET) can expand the number of breast cancer patients who can be treated with breast-conserving surgery and can predict benefit from adjuvant endocrine therapy. Because no validated surrogate markers for long-term outcome have been established, we conducted prospective trials to evaluate pathological response and Ki-67 index following treatment with tamoxifen or anastrozole. The study population included postmenopausal women with operable breast tumors that were both estrogen and progesterone receptor-positive and larger than 3 cm. Response was classified as pathological response (minimal response or better) and non-response. Non-responding (25.5%, vs. response 85.9%, p=0.002), axillary node-positive (58.4% vs. node negative 100%, p=0.045), and high pretreatment Ki-67 index (41.4% vs. low Ki-67 87.1%, p=0.03) patients were significantly associated with poor 5-year relapse-free survival. Multivariate analysis of relapse-free survival indicated that pathological response was independent. Therefore, pathological response may be a favorable prognostic factor after NAET.

Original languageEnglish
Pages (from-to)482-488
Number of pages7
JournalBreast
Volume16
Issue number5
DOIs
Publication statusPublished - Oct 2007
Externally publishedYes

    Fingerprint

Keywords

  • Breast cancer
  • Ki-67
  • Neoadjuvant endocrine therapy
  • Pathological response
  • Prognostic factor

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Akashi-Tanaka, S., Omatsu, M., Shimizu, C., Ando, M., Terada, K., Shien, T., Kinoshita, T., Fujiwara, Y., Seki, K., Hasegawa, T., & Fukutomi, T. (2007). Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy. Breast, 16(5), 482-488. https://doi.org/10.1016/j.breast.2007.02.003